![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 2 of 2. This is the beginning of the thread.
Posted by B2chica on May 27, 2011, at 12:26:10
this article is actually about how the trials in the us failed due to very high placebo effects, tested in i believe 4 other countries it rated very high...very curious about that aspect.
but reading about the drug itself sounds VERY promising to me. i listed some specs on med i found.
article also mentioned 3 or 4 other AD coming to trials, or to market soon.http://www.medscape.com/viewarticle/742964?sssdmh=dm1.690723&src=confwrap
Lu AA21004, which is currently in clinical development for MDD treatment, acts as a 5-HT3 and 5-HT7 receptor antagonist, a 5-HT1A receptor agonist, a 5-HT1B receptor partial agonist, and an inhibitor of the 5-HT transporter in recombinant cell lines.
It has also been found to increase extracellular levels of norepinephrine, dopamine, and acetylcholine in nonclinical studies, report the investigators.
Posted by Phillipa on May 27, 2011, at 13:20:53
In reply to New AD testing...and others coming also, posted by B2chica on May 27, 2011, at 12:26:10
All kinds of new testing seems to be arriving. Thanks Phillipa
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.